• 1 January 1984
    • journal article
    • research article
    • Vol. 68  (12) , 1483-1487
Abstract
The effect of different doses of 5-aza-2''-deoxycytidine (5-aza-dCyd) or cytarabine (ara-C) on the survival time of mice with intracerebral (ic) L1210 leukemia was compared. CD2F1 mice were given an ic inoculation of 103 L1210 cells, and chemotherapy was given as a 12 h i.v., infusion at various days thereafter. Treatment on day 6 with increasing doses of 5-aza-dCyd reached a mean maximal percent increase in lifespan (ILS) of 118% at 20 mg/kg; the mean maximal ILS reached for ara-C was .apprx. 60% at 1000 mg/kg. When these equitoxic doses of each drug, as determined by body wt loss, were given on day 3, 4 or 5, 5-aza-dCyd gave a greater ILS and more 60-day survivors than ara-C. Apparently, 5-aza-dCyd is more effective than ara-C against ic L1210 leukemia.